Alnylam Pharmaceuticals
ALNY
#378
Rank
HK$471.15 B
Marketcap
HK$3,566
Share price
-1.55%
Change (1 day)
82.00%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): HK$0.67

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is HK$0.70. In 2023 the company made an earnings per share (EPS) of -HK$27.48 an increase over its 2022 EPS that were of -HK$72.32.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)HK$0.67
2023-HK$27.48-62%
2022-HK$72.3229.03%
2021-HK$56.05-3.36%
2020-HK$58.00-8.48%
2019-HK$63.377.67%
2018-HK$58.8539.74%
2017-HK$42.1112.94%
2016-HK$37.2938.84%
2015-HK$26.86-32.88%
2014-HK$40.01259.44%
2013-HK$11.13-31.25%
2012-HK$16.19

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
-HK$9.73-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
HK$338.16 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-HK$21.33-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-HK$1.87-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-HK$5.68-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
HK$57.29 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
HK$28.85 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
HK$4.90 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel